Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
22 Aug 2018
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.
Stephen Padilla, 31 Aug 2018
Treatment with rivaroxaban results in less recurrent venous thromboembolism (VTE) in frail patients with VTE, with similar good bleeding outcomes, compared with warfarin, reports a study.
Stephen Padilla, 11 Sep 2018
Use of diclofenac, a traditional nonsteroidal anti-inflammatory drug (NSAID) with cyclo-oxygenase-2 (COX-2) selectivity similar to COX-2 inhibitors, is associated with higher cardiovascular health risk compared with nonuse, paracetamol use and use of other traditional NSAIDs, a recent study has shown.

No need to increase dose of influenza vaccine for haemodialysis patients

28 Aug 2019

The high-dose influenza vaccine (HDV) confers no additional protection beyond the standard-dose vaccine (SDV) in terms of all-cause mortality or influenza-related outcomes in adults undergoing maintenance haemodialysis, as shown in a recent study.

Researchers accessed the US Renal Data System and identified 507,552 adult patients who were undergoing in-centre maintenance haemodialysis between the 2010–2011 and 2014–2015 influenza seasons. Of the patients, 97.4 percent received SDV and 2.6 percent received HDV within 225,215 influenza patient-seasons.

Outcomes during the influenza season did not significantly differ between the HDV and SDV groups. The risk difference, obtained by propensity score weighting of Kaplan-Meier functions, was −0.08 percent (95 percent CI, −0.85 to 0.80) for all-cause mortality, 0.15 percent (−0.69 to 0.93) for hospitalization due to influenza or pneumonia, and 0.00 percent (−1.50 to 1.08) for influenza-like illness.

Results were similar in subgroups defined by age group, influenza season, dialysis vintage, month of influenza vaccination and vaccine valence.

In light of the present data, the researchers stressed that the additional cost and side effects associated with HDV should be considered when offering the vaccine.

The present study was limited by residual confounding and outcome misclassification. Additional research is needed to investigate HDV and other influenza vaccine strategies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
22 Aug 2018
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.
Stephen Padilla, 31 Aug 2018
Treatment with rivaroxaban results in less recurrent venous thromboembolism (VTE) in frail patients with VTE, with similar good bleeding outcomes, compared with warfarin, reports a study.
Stephen Padilla, 11 Sep 2018
Use of diclofenac, a traditional nonsteroidal anti-inflammatory drug (NSAID) with cyclo-oxygenase-2 (COX-2) selectivity similar to COX-2 inhibitors, is associated with higher cardiovascular health risk compared with nonuse, paracetamol use and use of other traditional NSAIDs, a recent study has shown.